SOTIO has stopped collaboration trial with the dendritic cell vaccine DCVAC in combination with ONCOS-102
Oslo, Norway, 9 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that collaboration partner SOTIO has stopped the combination trial assessing the combination of ONCOS-102 and DCVAC/PCa in prostate cancer. Only a very limited patient population fulfilled the strict inclusion criteria. Therefore, the recruitment could not meet originally planned numbers.The phase I trial prostate cancer study was paid for and run by the Czech biotech company SOTIO, investigating whether ONCOS-